Vertex Energy (VTNR) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one ...

Stifel: Analyst Paul Matteis adjusts the target price from $494 to $445, maintaining a hold rating. This mixed bag of ratings illustrates the cautious optimism surrounding Vertex Pharmaceuticals, as ...

Vertex Pharmaceuticals (NASDAQ: VRTX) is trading near a record high after climbing about 20% so far this year, and delivering a triple-digit gain over three years. So, you may be a bit hesitant about ...

Vertex Pharmaceuticals has built a billion-dollar cystic fibrosis business over time. But the company today may be preparing for a new era of growth, thanks to the strength of its pipeline. Vertex ...

Days before three scientists at Boston-based Vertex Pharmaceuticals will share a $3 million prize for revolutionizing the treatment of cystic fibrosis, the award — sometimes called the Oscars of ...

Vertex has built a billion-dollar business thanks to its expertise in treating cystic fibrosis. The biotech stock is cheaper today than it was earlier this year in relation to expected earnings. But ...

Vertex Pharmaceuticals has hit a snag in its efforts to follow up non-opioid pain reliever Journavx (suzetrigine). The Boston-based Big Biotech’s sodium channel inhibitor VX-993 failed to outpace ...

Vertex Pharmaceuticals will stay at its prominent headquarters on Fan Pier in Boston’s Seaport District after considering moving to another spot in the neighborhood, according to three real estate ...